ProQR Therapeutics BV, located in Leiden, the Netherlands, is a pioneering biopharmaceutical company dedicated to developing RNA-based therapies targeting severe genetic disorders. The company's robust pipeline includes a range of innovative treatments aimed at both rare and prevalent diseases, leveraging its proprietary technology platform to address the underlying genetic causes of these conditions. Committed to advancing genetic medicine, ProQR Therapeutics is strategically positioned to transform patient outcomes through its cutting-edge research and development initiatives, underscoring its role as a leader in this rapidly evolving field. Show more

Location: ZERNIKEDREEF 9, LEIDEN, NETHERLANDS, 2333 CK, Leiden, 2333 CK, USA | Website: https://www.proqr.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

153.8M

52 Wk Range

$1.07 - $3.10

Previous Close

$1.46

Open

$1.45

Volume

357,433

Day Range

$1.43 - $1.52

Enterprise Value

56.49M

Cash

106.9M

Avg Qtr Burn

-12.24M

Insider Ownership

18.10%

Institutional Own.

51.79%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AX-0810 Details NTCP for Cholestatic diseases	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AX-2911 (RNA Editing Oligonucleotide) Details Metabolic-Associated Steatohepatitis (PNPLA3 I148M)	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AX-2402 (RNA Editing Oligonucleotide) Details Rett Syndrome (MECP2 R270X)	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sepofarsen (QR-110) (CEP290 gene) Details Leber congenital amaurosis, Eye disease , Genetic disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ultevursen (QR-421a) (Exon 13) Details Mediated retinitis pigmentosa, Usher syndrome, Heart disease, Heart failure	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
QR-1123 (RNase H mediated cleavage) Details Mediated retinitis pigmentosa, Rho mediated retinitis pigmentosa	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
QR-504a Details Genetic disorder, Eye disease , Leber congenital amaurosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.